First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...
Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...
Johnson & Johnson announced positive topline results for the gold standard endpoint in cancer treatment of overall survival, or OS, from ...
Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...
Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung ...
Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved Rybrevant ...
Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...
1d
Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Genmab (GMAB – Research Report). The associated price target ...
PFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study.
Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung ...
Belgium: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the European Commission (EC) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback